(BMSIC/DRUGS/15-05)

	Technical Eligibility Criteria as per NIT	*Name of Bidder:- M/S Jackson laboratories(P)Ltd* *Corporate Address: 22-24,Majitha Road,Bye pass,Amritsar* *Manufacturing Unit Address:22-24,Majitha Road,Bye pass,Amritsar* *"Chart has been prepared on the basis of number of downloaded Pg. received (i.e.- 1-202) "*
1	Constitution of the Bidding Company/Firm such as Memorandum of Association and Article of Association with complete address. As per Clause 3(c).	MOA Submitted (pg no.78-87) Certificate of incorporation submitted (pg no.88)
2	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3 (e) of the NIT.	Resolution of board resolved that Mr,Jugal Kishore(MD) of company is hereby authorized to sign and submit on behalf of the board of directors vide their resolution dated 10.01.15 for the period of 2015-16 submitted (Page No. 76-77)
3	List of item Quoted in prescribed format as Annexure III as per Clause 3 (o)	**List of quoted Item-(Total quoted item 148)-Details as per enclosure**
4	• Minimum three years old valid manufacturing licence of the product quoted with latest license renewal certificate. As per clause 3(f). • Approved product list as per the license issued for quoted drugs for minimum three years. As per clause 3(f). • Manufacturing License along with approved product list must be valid till the last date of the submission of tender. As per clause 3(f). Bidders shall submit self attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. As per Clause 3(f)	Manufacturing licence in form 25 & form 28 bearing licence no 1307-OSP & 1308-B granted on 27.10.1987 submitted (pg no. 65& 63) Renewal in form 26 for Ml no.1307-OSP renewed from 1.1.13 to 31.12.2017 & for Ml no.1308-B in form 26 renewed from 1.1.2013 to 31.12.2017 submitted (pg no.66 & 67). **Approval of quoted items mentioned as per details in enclosure.Note :- Product approval not found in Submitted List of approval Drugs for Following NIT Sr. No. 14, 34, 37 ,43, 53, 59, 60, 67, 68, 83,144, 149, 151,154,155, 158 & 206**
5	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.As per Clause 3(g)	**NA**
6	Self attested copies of Market standing certificate (in India) of minimum three years, issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. As per Clause 3(h)	Self attested copies of Market standing certificate vide letter no.5842 dt 7.09.2015 of FDA Punjab,Chandigarh of quoted products submitted (Pg no.58-61) Details refer in Enclosure
7	Self attested copy of Non Conviction Certificate (NCC), issued by the concerned Licensing Authority from Drug Control Administration of the state for last three years. It should be not more than one year old. As per Clause 3(i).	Self attested copy of Non Conviction Certificate (NCC), issued by the Assistant Drug control cum licencing authority Punjab, Chandigarh vide no.12083 dated 18.05.15 Certified that the said firm does not stand convicted as on today. Submitted (Page No. 57) Another non Conviction Certificate vide No. 11872 dated 13.06.2014 Submitted (Page No. 56) Another non Conviction Certificate vide No. 18296 dated 23.09.2013 Submitted (Page No. 55)
8	Self attested copies of WHO-GMP/GMP as per revised Schedule-'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority / Drugs Control Department. The GMP certificate must not be older than one year form the last date of submission of tender. As per clause 3(j).	Self attested copies of GMP as per revised Schedule issued by Assistant Drug controlling and licencing authority Punjab, Chandigarh vide no.16249 dated 23.07.15 mentioning that this certificate is valid for a period of Two Years from the date of issue submitted (Page No. 54)
9	Self attested copies of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department highlighting the quoted product section. As per Clause 3(k).	Self attested copies of Notrised Certificate for Product Production details for Three Years (Years 2011-12/2012-13/2013-14) submitted for quated product NIT Sl. No. 99, 105, 111, 128, 129, 131, 132, 134, 139, 154, 155, 156, 169, 170, 184, 189, 190, 203, 204, 91, 46, 86, 142 & 157 (Page No. 26-52) Self attested copy of capacity and quality certification issued by C.A. dated 05.07.2010 and counter signed by Licencing authority Asst. Drugs controllar Punjab, Chandigarh singn on 07.07.2010 submitted where in the installed capacity of bidder firm is stated as : Tablets - 6,000 Lacks, Capsules - 1800 Lacks, Sachets - 120 Lacks, Vials - 60 Lacks, Bottels - 80 Lacks, Syrups, Suppositories Aerosols, Ampuls & IV Fluids - 450 Lacks. External Liquid - 60 Lack and Drops - 30 Lacks. (Page No. 170-171)
10	An affidavit sworn before first class magistrate/Notary stating that the firm & its quoted product is not black listed currently (as on the date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT).	An affidavit sworn before Notary stating that the firm & its quoted product is not black listed currently (as on the date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT). submitted (Page No. 21-25)
11	EMD details (DD number/BG number and date with issuing bank) as per Clause 3(b).	Rs. 3,00,000/-, DD No.- 915455, Punjab National Bank
12	Tender Fee Rs 10,000/- in form of DD as per Clause 3(a).	Rs. 10,000/-, DD No.- 915456, Punjab National Bank
13	Self attested copies of the Audited Annual Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 crores for any three of the last four consecutive financial years. (Auditor/ C.A. Certificate of turnover will not be accepted). As per Clause 3(l)	F.Y.- 2011-12, P-26-24 Rs. 20.477 Crore F.Y. -2012-13 P-23-21 Rs. 26.764 Crore Avg. T.O.- 25.479 Crore F.Y. 2013-14 P-20-18 Rs. 29.197 Crore
14	Self attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(m).	A.Y.- 2012-13 P- 10 A.Y.- 2013-14 P-11 A.Y.- 2014-15 P- 12
15	Self attested copy of PAN Card of the Bidder Company. As per Clause 3(p)	P-7
16	Self attested copy of Certificate of valid Sales tax/VAT registration of the bidder company. As per Clause 3(q)	P-8
17	Affidavit declaration regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT).	Affidavit declaration regarding acceptance of tender submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT). Submitted (Page No. 90)

The facts in clause No-1 to 10 and 17 of the provided sheet has been compiled with due deligence and care, on the basis of document provided by BMSICL, in compliance of letter No 515(15) Dt-21.08.2015 of Health Department, Govt of Bihar and letter no BMSIC/40010/2-2014/1678 Dt 18.09.2015 of GM (Supply Chain), BMSICL, Patna. Inspite, some inadvertent dicrepencies could have been crept in. Humble request to all concerned to bring to notice in due time, if any discrepencies is observed, for rectification.

	The facts in pages mentioned against the clause No-1 to 10 and 17 of this chart has been verified.	Yashwant	

	Jackson laboratories(P)Ltd					
	PRODUCT LIST APPROVAL & MARKET STANDING STATUS					
S No	NIT S No	Product Name	Product Approval date/validity(Pg No)/Sl.no	Remarks	Market Standing for more than three years (Pg No)/Sl.no	Remarks
1	5	Dextrose Injection IP (Form, Fill & Seal Process) 50% w/v-25 ml	5.4.10/31.12.2017(169/53)	FFS not specified	61/01	
2	6	Albendazole oral suspn.IP-200mg/5ml 10ml	4.2.10(168/1)	i)validity not mentioned ii)pack size not mentioned iii)Specification given under USP Whereas NIT Specification is in IP	61/02	Specification under IP & Pack size not mentioned
3	7	Albendazole Tablets IP 400mg	16.9.09/31.12.17(167/82)		61/03	
4	8	Alprazolam Tablets IP 0.5mg	1.1.08/31.12.2012(166 A/2)	Validity upto 31.12.2012	61/04	
5	9	Amikacin Injection IP 100mg/2ml- 2ml	15.10.05(166B/1)	i)validity not mentioned ii)pack size not mentioned	61/05	pack size not mentioned
6	10	Amikacin Injection IP 250mg/2ml- 2ml	4.02.10(98/1)	i)validity not mentioned ii)Specification given under USP Whereas NIT Specification is in IP iii)Pack size not mentioned	61/06	Specification under IP & Pack size not mentioned
7	11	Aminophyline Inj. IP, 25mg/ml- 10ml	16.9.09/31.12.2017(165/1)	i)pack size not mentioned	61/07	pack size not mentioned
8	12	Amitriptyline Tablets IP 25mg	16.9.09/31.12.2017(164/2)		61/08	
9	13	Amlodipine Tablets IP 5 mg	25.4.2011/31.12.2017(163/1)		61/09	
10	14	Amoxycillin+Cloxacillin (125 mg + 125 mg)/5ml-60ml	Approval not submitted		61/10	
11	15	Amoxycillin and Potassium Clavulanate Oral Suspn. (200+28.5)mg-30ml	1.1.2008/31.12.2017(162/10)	Pack size not mentioned	61/11	pack size not mentioned
12	16	Amoxycillin Capsule IP, 500mg	1.12008/31.12.2017(161/2)		61/12	
13	17	Amoxycillin Capsule IP, 250mg	1.12008/31.12.2017(161/1)		61/12	
14	18	Amoxycillin Dispersible Tablets IP, 125mg-kid Tab.	1.1.2008/31.12.2017(160/2)		61/13	
15	19	Amoxycillin Oral Suspension IP, 125mg/5ml-60ml	1.1.2008/31.12.2017(162/2)	Pack size not mentioned	61/14	pack size not mentioned
16	20	Amplicillin & Cloxacillin Inj. (500+500)mg-vial	16.9.2009/31.12.2017(159/2)		61/16	
17	21	Amplicillin & Cloxacillin Inj. (250+250)mg-vial	16.9.2009/31.12.2017(159/1)		61/15	
18	22	Amplicillin Inj. IP, 500mg- Vial	11.10.2005(158/3)	Validity not mentioned	61/17	
19	23	Antacid Tablets (Dried Aluminium Hydroxide Gel- 250, Mag Hydroxide - 250 mg, Activated Dimethicon 50 mg	4.2.10/31.12.2017(157/66)		61/18	
20	25	Atenolol Tab. IP, 25mg	1.1.2008/31.12.12(166A/3)	Validity upto 31.12.2012	61/19	
21	26	Atenolol Tab. IP, 50mg	1.1.2008/31.12.12(166A/4)	Validity upto 31.12.2012	61/19	
22	28	Atropine Injection IP 0.6mg/ml-1ml	11.10.2005(166B/4)	Validity not mentioned	61/20	

23	29	Azithromycin Oral Suspension IP, 200mg/5ml- 15ml	1.1.2008/31.12.2017(162/3)	Pack size not mentioned	60/21	Pack size not mentioned
24	31	Bupivacaine Hydrochloride Injection IP, 0.5 %(5mg/ml)-20ml	16.9.2009/31.12.17(165/4)	Pack size not mentioned	60/22	Pack size not mentioned
25	34	Calcium Carbonate Tablets IP(Calcium Carbonate equivalent to 250mg elemental calium)	Approval not submitted			
26	35	Calcium Gluconate Injection IP, 100mg/ml-10ml	16.9.2009/31.12.17(165/6)	Pack size not mentioned	60/23	Pack size not mentioned
27	36	Calcium Tablets (Calcium Carbonate euivalent to 500mg elemental calcium and vit D3-250 I.U	4.2.10/31.12.2017(155/12)		60/24	Composition of Vit D3 mentioned as 250mg
28	37	Carbamazepine Oral Suspension, 20mg/ml-100ml	Approval not submitted		60/25	Pack size not mentioned
29	38	Carbamazepine Tablets IP 200mg	6.12.2009/31.12.2017(154/38)		60/26	
30	39	Carbamazepine Tablets IP 100mg	13.8.2012/31.12.2017(153/20)		60/26	
31	40	Cefadroxil Oral Suspension IP, 125 mg/ 5ml-30ml	1.1.2008/31.12.2017(162/9)	Pack size not mentioned	60/27	Pack size not mentioned
32	41	Cefadroxil Tab. 500mg	11.10.2005(166A/7)	Validity not mentioned	60/28	
33	42	Cefixime Tab. IP 50mg	4.2.2010(152/4)	Validity not mentioned	60/29	
34	43	Cefixime Oral suspension IP, 100mg/5ml- 30ml	Approval not submitted		60/30	Pack size not mentioned
35	44	Cefixime tab. IP, 100mg	16.9.2009/31.12.2017(151/5)		60/31	
36	45	Cefixime Tab. 400mg	4.2.10/31.12.2017(150/8)		60/31	
37	46	Cefotaxime Sodium Inj. IP, 1gm- Vial	16.9.2009/31.12.2017(149/7)		60/32	
38	47	Cefotaxime Sodium Inj. IP, 250mg- Vial	16.9.2009/31.12.2017(149/5)		60/32	
39	48	Cefotaxime Sodium Inj. IP, 500mg- Vial	16.9.2009/31.12.2017(149/6)		60/32	
40	49	Cefotaxime Sodium Inj. IP, 125mg-vial	4.2.2010(148/1)	i)Validity not mentioned ii)Name given under BP Specification & composition description under IP Specification)	60/32	
41	50	Ceftazidime Inj. IP, 500mg-Vial	16.9.2009/31.12.2017(147/16)		60/33	
42	51	Ceftazidime Inj. IP, 250mg-Vial	16.9.2009/31.12.2017(147/15)		60/33	
43	52	Ceftazidime Inj. IP, 1g-Vial	16.9.2009/31.12.2017(147/17)		60/33	
44	53	Ceftriaxone & Salbactum For Inj. 500mg+250mg- Vial	Approval not submitted			
45	54	Ceftriaxone & Salbactum For Inj. 250mg+125mg- Vial	4.2.2010(146/3)	Validity not mentioned	60/34	
46	55	Cetriaxone Inj. IP, 250mg-Vial	16.9.2009/31.12.2017(145/8)		60/35	
47	56	Cetriaxone Inj. IP, 500mg-Vial	16.9.2009/31.12.2017(145/9)		60/35	
48	57	Cefuroxime Axetil Tab. IP, 125mg	13.8.12/31.12.2017(144/4)		60/36	
49	59	Cetrizine Syrup IP, 5mg/5ml-30ml	Approval not submitted			
50	60	Chloramphenicol Eye Ointment IP, 1% w/w -5gm tube	Approval not submitted			
51	63	Chlorpheniramin Tablets IP 4mg	16.9.2009/31.12.2017(141/15)		60/38	
52	64	Ciprofloxacin Eye Drops IP, 0.3% w/v- 5ml Pack	01.01.2008/31.12.2017 (140/4)	Pack size not mentioned	60/39	Pack size not mentioned
53	65	Ciprofloxacin Hydrochloride Tab. IP, 250mg	16.09.2009/31.12.2017 (139/19)		60/40	
54	67	Clindamycin Inj. IP, 150mg/ml-2ml Amp/Vial	Approval not submitted		60/42	Pack size not mentioned
55	68	Clonazepam Tablets IP 0.5mg	Approval not submitted		60/43	

56	75	Dexamethosone Inj. IP, 4mg/ml-2ml Vial	11.10.2005/ (166B/7)	(i) Validity not mentioned (ii) Pack size not mentioned	60/44	Pack size not mentioned
57	76	Dexamethosone Inj. IP, 4mg/ml-10ml Vial	11.10.2005/ (166B/7)	(i) Validity not mentioned (ii) Pack size not mentioned	60/44	Pack size not mentioned
58	77	Diazapam Injection IP 5mg/ml-2ml	11.10.2005/ (166B/8)	(i) Validity not mentioned (ii) Pack size not mentioned	60/45	Pack size not mentioned
59	78	Diazepam Tablets IP 5mg	16.09.2009/31.12.2017 (138/31)		60/46	
60	80	Diclofenac Sodium Gastro- Resistant Tablets IP 50mg	01.01.2008/31.12.2012 (166A/8)	Not as per NIT specification	60/47	Namenclature as Tab.Diclofenac sodium IP 50mg
61	81	Dicyclomine HCL and Paracetamol (20 mg+ 325 mg)	04.02.2010/31.12.2017(156/101)	Not as per NIT specification (20+500) mg	60/48	Not as per NIT specification
62	82	Dicyclomine Hydrochloride Tablets IP20mg	13.08.2012/31.12.2017 (101/18)		60/49	
63	83	Dicyclomine Hydrochloride Injection IP 10 mg/ml - 2ml Amp.	Approval not submitted		60/50	Pack size not mentioned
64	84	Diethylcarbamazine Tabltes IP 50 mg	16.09.2009/31.12.2017 (138/32)		60/51	
65	85	Dobutamine Injection (50mg/ml) - 5ml Amp./Vial	04.02.2010 (137/1)	(i) Validity not mentioned (ii) Pack size not mentioned	60/52	
66	86	Dopamine Injection Injection IP (40 mg/ml) - 5ml. Amp.	04.02.2010 (136/5)	(i) Validity not mentioned (ii) Pack size not mentioned	60/53	
67	87	Doxycycline Cap. IP, 100mg	16.09.2009/31.12.2017 (135/11)		60/54	
68	88	Drotaverine Hydrochloride Inj. 40mg/2ml-2ml Amp.	04.02.2010 (137/3)	(i) Validity not mentioned (ii) Pack size not mentioned (ii) Composition not as per NIT (40 mg/2ml whereas approval is of 40 mg/ml)	60/55	Pack size not mentioned
69	89	Etophylline & Theophylline Inj. (169.4+50.6)mg/ 2ml- 2ml Amp.	05.04.2010/31.12.2017 (134/7)		60/56	
70	90	Etophyline+ Theophylline Prolonged release Tablets (35 mg+115mg)	04.02.2010/31.12.2017 (133/16)		60-59/57	
71	91	Fluoxetine Capsules IP20mg	21.01.2009/31.12.2017 (132/9)	**Approval in USP**	59/58	
72	93	Frusemide Injection IP10 mg/ml - 2 ml. Amp.	05.04.2010/31.12.2017 (169/56)		59/59	
73	94	Frusemide Tablest IP 40 mg	06.12.2009/31.12.2017 (154/42)		59/60	
74	98	Gentamicin Inj. IP, 40mg/ml-2ml Vial	05.04.2010/31.12.2017 (130/19)		59/61	
75	99	Glycopyrrolate Injection0.2mg/ml - 1 ml. Amp.	04.02.2010 (129/3)	(i) Validity not mentioned (ii) Pack size not mentioned	59/62	Pack size not mentioned
76	100	Haloperidol Injection IP 5mg/ml - 1ml. Amp.	05.04.2010/31.12.2017 (130/20)		59/63	
77	103	Hydrochlorothiazide Tablets IP 25 mg	21.01.2009 (128/2)	Validity not mentioned	59/64	
78	104	Hydrochlothiazide Tablets IP 50 mg	21.01.2009 (128/3)	Validity not mentioned	59/64	
79	105	Hydrocortisone Sodium Succinate Inj. IP, 100mg vial	16.09.2009/31.12.2017 (127/25)		59/65	

80	106	Iron and Folic Acid Syrup IP, 100mg+ 0.5 mg - 200 ml bottel	04.02.2010 (126/5)	(i) Validity not mentioned (ii) Pack size not mentioned	59/66	Pack size not mentioned
81	107	Iron and Folic Acid Tab (20 mg + 100mg)	16.09.2009/31.12.2017 (125/3)		59/67	
82	111	Isosorbide Dinitrate Tablets IP, 10 mg	25.04.2011/31.12.2017 (124/41)		59/68	
83	112	Isosorbide Dinitrate Tablets IP, 5mg	25.04.2011/31.12.2017 (124/40)		59/68	
84	113	Isosorbide Mononitrate Tablets IP 10 mg	25.04.2011/31.12.2017 (124/42)		59/69	
85	114	Isosorbide Mononitrate Tablets IP 20 mg	04.02.2010 (123/2)	Validity not mentioned	59/69	
86	115	Isoxsuprine Injection IP 5 mg/ ml - 2ml. Amp.	05.04.2010/31.12.2017 (122/24)		59/70	
87	116	Isoxsuprine Tablets IP 20 mg	16.09.2009/31.12.2017 (21/53)		59/71	
88	117	Ketamine Hydrochloride Injection IP 10 mg/ ml - 10ml. Amp.	05.04.2010/31.12.2017 (22/25)		59/72	
89	119	Lignocaine and Dextrose Injection IP (5 %+75 mg/ml) - 2ml. Amp.	05.04.2010/31.12.2017 (120/5)		59/73	
90	121	Lignocaine Hydrochloride Injection IP 1 %w/v - 30ml. Vial	05.04.2010/31.12.2017 (122/27)		59/74	
91	122	Lignocaine Hydrochloride Injection IP 2 %w/v - 30 ml. vial	05.04.2010/31.12.2017 (120/1)		59/74	
92	123	Lorazepam Injection IP 2 mg/ml - 2 ml. vial	09.04.2010/31.12.2017 (119/1)	Approval under BP/USP	59/75	Specification under IP
93	124	Magnesium Sulphate Injection IP 500 mg/ml - 5 ml. Amp.	05.04.2010/31.12.2017 (120/9)	(i) Not approved 5 ml. Amp. (ii) Approved under USP	59/76	Specification under IP & Pack size not mentioned
94	126	Mefenamic Acid Capsules IP 250mg	04.02.2010 (18/4)	Validity not mentioned	59/77	
95	127	Mephentermine Injection IP 30 mg/ml-10ml vial	09.04.2010/31.12.2017 (119/15)		59/78	
96	128	Meropenem Inj. IP, 500mg-Vial	24.02.2010 (117/1)	Validity not mentioned	59/79	
97	129	Meropenem Inj. IP, 1000mg-Vial	24.02.2010 (117/2)	Validity not mentioned	59/79	
98	130	Metoclopramide Inj. IP, 5mg/ml-2ml Amp.	05.04.2010/31.12.2017 (120/7)		59/80	
99	131	Methylergometrine Inj. IP, 0.2mg/ml-1ml Amp.	05.04.2010/31.12.2017 (120/6)		59/81	
100	132	Methylergometrine Tab. 0.125 mg	16.09.2009/31.12.2017 (167/84)		59/82	
101	133	Methylprednisolone Acetate Injection IP 40 mg/ml-2 ml	05.04.2010/31.12.2017 (116/24)		59/83	
102	134	Metoclopramide Tab. IP 10 mg	16.09.2009/31.12.2017 (115/97)		59/84	
103	139	Midazolam Inj. IP, 1mg/ml-5ml vial	09.04.2010/31.12.2017 (119/11)	Approval under BP	59/85	
104	140	Midazolam Inj. IP, 5mg/ml-1ml vial	09.04.2010/31.12.2017 (119/11)	Approval under BP and composition of 5mg/ml not mentioned in the Approval.	59/85	
105	141	Misoprostol Tab. IP 100 µcg	20.04.2011/31.12.2017 (114/28)		59/86	
106	142	Misoprostol Tab. IP 200 µcg	20.04.2011/31.12.2017 (114/29)		59/86	
107	144	Multivitamins Sch. V	Approval not submitted		59/87	As Multivitamin NFI
108	145	Neostigmine Methylsulphate Injection IP 0.5 mg/ml - 1ml	05.04.2010/31.12.2017 (130/16)		59/88	
109	146	Nikethamide Inj. IP 25% w/v- 2ml	05.04.2010/31.12.2017 (130/13)		59/89	
110	147	Norethisterone Tablets IP 5 mg	04.02.2010/31.12.2017 (112/3)		59/90	
111	148	Ofloxacin & Ornidazole suspen. (50+125)mg/30ml bottle	04.02.2010 (126/1)	(i) Validity not mentioned (ii) Pack size not mentioned	59/91	Pack size not mentioned
112	149	Ofloxacin Infusion IP (Form, Fill & Seal Process) 200 mg/100ml - 100 ml	Approval not submitted			

Yashwant

113	150	Ofloxacin Ophthalmic Solution IP 0.3 % w/v - 10 ml Pack	04.02.2010 (111/5)	(i) Validity not mentioned (ii) Pack size not mentioned	59/92	
114	151	Ofloxacin Oral Suspension IP 50 mg/5ml - 30 ml	Approval not submitted		59/93	Pack size not mentioned
115	152	Ondansetron Hydrochloride Inj. 2mg/ml- 2ml Amp.	3.4.2010/31.12.2017(110/8)		59/94	Pack size not mentioned
116	153	Ondansetron Oral Solution IP, 2mg/5ml-30ml	4.2.2010(109/47)	(i) Validity not mentioned (ii) Pack size not mentioned	59/95	Pack size not mentioned
117	154	Ondansetron Tab. IP, 4 mg	Approval not submitted	The highlighted quoted product approval for Injection(pg no.137/6)	59/96	
118	155	Ondansetron Tab. IP, 8 mg	Approval not submitted	The highlighted quoted product approval for Injection(pg no.137/7)	59/96	
119	156	Oxytocin Inj. IP, 5units/ml-1ml Amp.	5.4.2010/31.12.2017(122/28)		59/97	
120	157	Pantoprazole for Inj. 40mg Vial	4.2.2010/31.12.2017(108/16)		58/98	
121	158	Paracetamol Paediatric Oral Suspension 50 mg/ml - 15 ml	Approval not submitted		58/99	Pack size not mentioned
122	160	Pheniramine Injection IP 22.75 mg/ml - 2 ml	5.4.2010/31.12.2017(107/35)		58/101	
123	161	Phenobarbitone Syrup 20 mg / 5ml-60ml	4.2.2010(106/2)	(i) Validity not mentioned (ii) Pack size not mentioned	58/102	Pack size not mentioned
124	162	Phenytoin Injection IP 50mg/ml-2ml	5.04.2010/31.12.2017(107/31)		58/103	
125	163	Phenytoin Oral Suspension IP 25 mg/ml-100ml	4.2.2010(142/6)	(i) Validity not mentioned (ii) Pack size not mentioned	58/104	Pack size not mentioned
126	165	Piperacillin & Tazobactum for inj. (4g+500mg)-4.5gm vial	4.2.2010/31.12.2017(108/21)		58/106	
127	169	Prednisolone Tab. IP 5mg	16.9.2009/31.12.2017(121/60)		58/107	
128	170	Prednisolone Tab. IP 10mg	16.9.2009/31.12.2017(121/61)		58/107	
129	171	Promethazine Syrup IP 5mg/5ml-60ml	4.2.2010(142/10)	(i) Validity not mentioned (ii) Pack size not mentioned	58/108	Pack size not mentioned
130	177	Rabeprazole Gastro-Resistant Tab. IP 20mg	4.2.2010/31.12.2017(105/21)	IP Specification not mentioned	58/110	
131	179	Ranitidine Tab.IP 150mg	16.9.2009/31.12.2017(103/79)		58/111	
132	181	Salbutamol Tablets IP 4mg	16.9.2009/31.12.2017(103/72)		58/112	
133	182	Salbutamol Tablets IP 2mg	16.9.2009/31.12.2017(101/71)		58/112	
134	184	Sodium Bicarbonate Injection IP 7.5% w/v - 25 ml	5.4.2010/31.12.2017(107/39)		58/113	
135	186	Sodium Valproate Oral Solution IP 200 mg/ 5ml - 100 ml	4.2.2010(100/7)	(i) Validity not mentioned (ii) Pack size not mentioned	58/114	Pack size not mentioned

Yashwant

136	187	Sodium Valproate Tab. IP 500 mg	13.8.2012/31.12.2017(153/12)		58/115	
137	188	Sodium Valproate Tab. IP 200 mg	16.9.2009/31.12.2017(101/69)		58/115	
138	189	Spironolactone Tab. IP 50 mg	4.2.2010(99/2)	Validity not mentioned	58/116	
139	190	Spironolactone Tab. IP 100 mg	16.9.2009(97/10)	Validity not mentioned	58/116	
140	198	Tramadol Hydrochloride Inj. 50mg/ml - 2ml	5.4.2010/31.12.2017(110/1)	Validity not mentioned	58/117	
141	199	Tranexamic Acid Inj. IP 100mg/ml - 5ml	4.2.2010(95/5)	(i) Validity not mentioned (ii) Pack size not mentioned	58/118	Pack size not mentioned
142	200	Tranexamic Acid Tab. IP 500mg	4.2.2010(94/4)	Validity not mentioned	58/119	
143	201	Trifluoperazine and Trihexylphenidyl Tab. (Each film coated tab: Trifluoperazine Hydrochloride IP 5 mg & Trihexylphenidyl HCL IP 2mg)	4.2.2010/31.12.2017(93/110)		58/120	
144	202	Valethemate Bromide Inj. 8mg/ml - 1ml	4.2.2010(92/5)	Validity not mentioned	58/121	
145	203	Vancomycin Intravenous Infusion IP 1000 mg - vial	4.2.2010/31.12.2017(108/20)	i)Specification not as per NIT,Approval under BP/USP	58/122	Specification under IP
146	204	Vancomycin Intravenous Infusion IP 500 mg - vial	4.2.2010/31.12.2017(108/19)	i)Specification not as per NIT,Approval under BP/USP	58/122	Specification under IP
147	206	Vincristine Inj. IP 1mg/ml - vial	Approval not submitted		58/123	
148	207	Vitamin B Complex Tab. (For Prophylactic Use Only) As per Sch. V	16.9.2009/31.12.2017(91/2)		58/124	

Yashwant